Context Therapeutics (NASDAQ:CNTX) Earns “Buy” Rating from D. Boral Capital

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reiterated by D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price objective on the stock.

A number of other research analysts have also recently commented on CNTX. Guggenheim initiated coverage on shares of Context Therapeutics in a research report on Thursday, September 18th. They set a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th. HC Wainwright boosted their target price on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald initiated coverage on shares of Context Therapeutics in a research report on Thursday, October 2nd. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Context Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $5.40.

Context Therapeutics Stock Up 1.8%

CNTX opened at $1.13 on Thursday. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $2.32. The company has a 50 day moving average of $1.06 and a two-hundred day moving average of $0.85. The company has a market cap of $101.36 million, a P/E ratio of -3.14 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Trading of Context Therapeutics

An institutional investor recently raised its position in Context Therapeutics stock. Clear Harbor Asset Management LLC raised its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,804 shares of the company’s stock after purchasing an additional 35,000 shares during the period. Clear Harbor Asset Management LLC owned about 0.10% of Context Therapeutics worth $90,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.